Table 1.
Treatment | Patient | Tideglusib administration | Age (y) | Gender | AChE‐I treatment | AChE‐I treatment duration (y) |
---|---|---|---|---|---|---|
Placebo | 1 | 72 | M | Donepezil | 2.0 | |
2 | 80 | M | Donepezil | 5.0 | ||
3 | 83 | M | Rivastigmine | 0.8 | ||
4 | 61 | F | Donepezil | 2.0 | ||
5 | 78 | F | Galantamine | 2.0 | ||
Tideglusib | 6 | QOD | 64 | M | Galantamine | 1.1 |
7 | QOD | 59 | F | Rivastigmine | 1.0 | |
8 | QD | 68 | F | Galantamine | 3.2 | |
9 | QOD | 78 | M | Rivastigmine | 0.4 | |
10 | QD | 66 | M | Donepezil | 3.4 | |
11 | QOD | 71 | M | Rivastigmine | 1.3 | |
12 | QOD | 63 | M | Rivastigmine | 0.5 | |
13 | QD | 81 | M | Rivastigmine | 1.9 | |
14 | QD | 73 | M | Galantamine | 0.9 | |
15 | QD | 68 | M | Rivastigmine | 1.1 | |
16 | QOD | 76 | M | Donepezil | 1.8 | |
17 | QD | 68 | F | Donepezil | 2.4 | |
18 | QD | 65 | F | Donepezil | 4.81 | |
19 | QOD | 77 | M | Donepezil | 1.93 |
AD patients were administered with placebo or 1,000 mg of tideglusib orally using two different regimes: once a day (QD) and every other day (QOD).
F/M, female/male. All AD patients were under AChE inhibitor (AChE‐I) treatment for at least 4 months prior to the enrollment into the trial. AChE‐I tratmen duration (years, Y) is indicated.